Advanced Renal Cell Carcinoma: Interpreting Emerging Evidence for Belzutifan-Based Therapies

Dr. Monty Pal reviews emerging clinical evidence evaluating belzutifan-based treatment strategies in advanced renal cell carcinoma (RCC), with particular focus on the LITESPARK-011 trial comparing lenvatinib plus belzutifan with cabozantinib. He discusses the reported progression-free survival benefit observed with the combination regimen while highlighting important considerations regarding the translation of clinical trial findings into routine practice. Drawing upon his own clinical experience, Dr. Pal explains that maintaining the full intended dose of lenvatinib can be challenging in everyday practice and suggests that dose reductions may influence the real-world effectiveness of lenvatinib-based combinations. He also considers toxicity profiles, including anemia and hypoxia associated with belzutifan, alongside gastrointestinal adverse events associated with tyrosine kinase inhibitors when evaluating treatment options. Throughout the discussion, Dr. Pal emphasizes the importance of critically interpreting emerging evidence and integrating efficacy, tolerability, and practical implementation when selecting subsequent therapies for patients with advanced renal cell carcinoma.